A randomized, double-blind, parallel-group, pharmacokinetic study of oral SCIO-469 (90 mg qd and 30 mg Tid) in female subjects with active rheumatoid arthritis.

Trial Profile

A randomized, double-blind, parallel-group, pharmacokinetic study of oral SCIO-469 (90 mg qd and 30 mg Tid) in female subjects with active rheumatoid arthritis.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2010

At a glance

  • Drugs Methotrexate; Methotrexate; Talmapimod
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Scios
  • Most Recent Events

    • 22 Oct 2007 Status changed from in progress to completed.
    • 03 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top